Collegium Pharmaceutical (COLL) Cash from Operations Growth (3y) (2017 - 2026)
Collegium Pharmaceutical (COLL) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Collegium Pharmaceutical | 887.15 Mn | 737.84 Mn | 110.29 Mn | -10.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.57% |
| Mar 31, 2026 | 27.32% |
| Dec 31, 2025 | 22.88% |
| Sep 30, 2025 | 22.40% |
| Jun 30, 2025 | 21.44% |
| Mar 31, 2025 | 61.19% |
| Dec 31, 2024 | 32.73% |
| Sep 30, 2024 | -36.11% |
| Jun 30, 2024 | 31.65% |
| Mar 31, 2024 | 44.40% |
| Dec 31, 2023 | 48.10% |
| Sep 30, 2023 | 29.38% |
| Jun 30, 2023 | 31.50% |
| Mar 31, 2023 | 83.21% |
| Dec 31, 2022 | 61.81% |
| Sep 30, 2022 | 91.72% |
| Jun 30, 2022 | 40.36% |
| Mar 31, 2022 | -43.49% |
| Dec 31, 2021 | -5.05% |
| Sep 30, 2021 | -25.56% |